Skip to main content
Top

28-06-2018 | Rheumatoid arthritis | Article

The subjective components of the Disease Activity Score 28-joints (DAS28) in rheumatoid arthritis patients and coexisting fibromyalgia

Journal: Rheumatology International

Authors: Fausto Salaffi, Marco Di Carlo, Marina Carotti, Piercarlo Sarzi-Puttini

Publisher: Springer Berlin Heidelberg

Abstract

To determine the contribution of fibromyalgia (FM) to the subjective components of the Disease Activity Score 28-joints (DAS28) in patients with rheumatoid arthritis (RA), and to analyse the discriminatory performance of the derived DAS28 patient-reported components (DAS28-P) to identify patients with fibromyalgic RA. Consecutive RA patients underwent clinical and clinimetric assessment. The DAS28-P index was derived from the components of the DAS28 scores by rearranging the DAS28-ESR formula. Patients were distinguished by the presence of FM. Student parametric t tests or Mann–Whitney non-parametric U tests were used to determine any between-group differences. Receiver operating characteristic (ROC) curve analysis was used to test the ability of the DAS28-P index to distinguish patients with RA and those with fibromyalgic RA. The study involved 292 RA patients (80.5% females, mean age 63 years) with a mean disease duration of 11.6 ± 8.5 years. Forty-three patients (14.7%) had concomitant FM, and significantly higher tender joint count (p < 0.001), pain numerical rating scale, global health status (p = 0.007), and DAS28 scores (p = 0.006) than those without FM. The DAS28-P values were also significantly higher in the patients with FM (0.68 ± 0.09 vs 0.58 ± 0.06; p < 0.001). The discriminatory power of the DAS28-P was very good (area under the ROC of 0.858, optimal cut-off value of 0.631). The presence of FM strongly influences the DAS28 results. The assessment of patient-reported components to the DAS28 through the DAS28-P can be a useful way to identify patients with fibromyalgic RA.
Literature
1.
Salaffi F, De Angelis R, Stancati A, Grassi W, MArche Pain; Prevalence INvestigation Group (MAPPING) study (2005) Health-related quality of life in multiple musculoskeletal conditions: a cross-sectional population based epidemiological study. II. The MAPPING study. Clin Exp Rheumatol 23:829–839PubMed
2.
Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25CrossRefPubMedPubMedCentral
3.
Scott DL, Steer S (2007) The course of established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:943–946CrossRefPubMed
4.
Wolfe F, Michaud K (2009) Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis. J Rheumatol 36:831–836CrossRefPubMed
5.
Wolfe F, Cathey MA, Kleinheksel SM (1984) Fibrositis (fibromyalgia) in rheumatoid arthritis. J Rheumatol 11:814–818PubMed
6.
Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19–28CrossRefPubMed
7.
Ranzolin A, Brenol JC, Bredemeier M, Guarienti J, Rizzatti M, Feldman D et al (2009) Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 61:794–800CrossRefPubMed
8.
Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A (2014) Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int 34:1275–1280CrossRefPubMed
9.
Salaffi F, De Angelis R, Stancati A, Grassi W, MArche Pain; Prevalence INvestigation Group (MAPPING) study (2005) Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. The MAPPING study. Clin Exp Rheumatol 23:819–828PubMed
10.
Salaffi F, Gerardi MC, Atzeni F, Batticciotto A, Talotta R, Draghessi A et al (2017) The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 37:2035–2042CrossRefPubMed
11.
Durán J, Combe B, Niu J, Rincheval N, Gaujoux-Viala C, Felson DT (2015) The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort. Rheumatology 54:2166–2170PubMedCrossRefPubMedCentral
12.
Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA (2006) Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 24:S77–S82
13.
Ton E, Bakker MF, Verstappen SM, Ter Borg EJ, van Albada-Kuipers IA, Schenk Y et al (2012) Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol 39:22–27CrossRefPubMed
14.
Pollard LC, Kingsley GH, Choy EH, Scott DL (2010) Fibromyalgic rheumatoid arthritis and disease assessment. Rheumatology 49:924–928CrossRefPubMed
15.
Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B (2004) The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology 43:1504–1507CrossRefPubMed
16.
Pollard LC, Ibrahim F, Choy EH, Scott DL (2012) Pain thresholds in rheumatoid arthritis: the effect of tender joint counts and disease duration. J Rheumatol 39:28–31CrossRefPubMed
17.
Lee YC, Chibnik LB, Lu B, Wasan AD, Edwards RR, Fossel AH et al (2009) The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 11:R160CrossRefPubMedPubMedCentral
18.
McWilliams DF, Zhang W, Mansell JS, Kiely PD, Young A, Walsh DA (2012) Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. Arthritis Care Res 64:1505–1513CrossRef
19.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefPubMed
20.
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS et al (2011) Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 38:1113–1122CrossRefPubMed
21.
Sarzi-Puttini P, Atzeni F, Masala IF, Salaffi F, Chapman J, Choy E (2018) Are the acr 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria? Autoimmun Rev 17:33–35CrossRefPubMed
22.
Salaffi F, Bazzichi L, Stancati A, Neri R, Cazzato M, Consensi A et al (2005) Development of a functional disability measurement tool to assess early arthritis: the recent-onset arthritis disability (ROAD) questionnaire. Clin Exp Rheumatol 23:628–636PubMed
23.
Stucki G, Liang MH, Stucki S, Bruhlmann P, Michel BA (1995) A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research: psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 38:795–798CrossRefPubMed
24.
Salaffi F, Stancati A, Neri R, Grassi W, Bombardieri S (2005) Measuring functional disability in early rheumatoid arthritis: The validity, reliability and responsiveness of the Recent-Onset Arthritis Disability (ROAD) index. Clin Exp Rheumatol 23:S31–S42PubMed
25.
Salaffi F, Franchignoni F, Giordano A, Ciapetti A, Gasparini S, Ottonello M (2013) Classical test theory and Rasch analysis validation of the Recent-Onset Arthritis Disability questionnaire in rheumatoid arthritis patients. Clin Rheumatol 32:211–217CrossRefPubMed
26.
Norman GR, Streiner DL (1994) Biostatistics: the bare essentials. Mosby, St. Louis
27.
Swetz JA (1988) Measuring accuracy of diagnostic systems. Science 240:1285–1293CrossRef
28.
Heiberg T, Kvien TK (2002) Preferences for improved health examined in 1024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 47:391–397CrossRefPubMed
29.
Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M et al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499–510CrossRefPubMed
30.
Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–88CrossRefPubMed
31.
Rachapalli SM, Williams R, Walsh DA, Young A, Kiely PD, Choy EH (2010) First-line DMARD choice in early rheumatoid arthritis: do prognostic factors play a role? Rheumatology 49:1267–1271CrossRefPubMed
32.
Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K et al (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 64:640–647CrossRef
33.
Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1–26PubMed
34.
Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM et al (2015) APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 18:685–713CrossRefPubMed
35.
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509CrossRefPubMed
36.
Wolfe F, Cathey MA (1983) Prevalence of primary and secondary fibrositis. J Rheumatol 10:965–968PubMed
37.
Lee YC, Lu B, Boire G, Haraoui BP, Hitchon CA, Pope JE et al (2013) Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. Ann Rheum Dis 72:949–954CrossRefPubMed
38.
Wolfe F, Hauser W, Hassett AL, Katz RS, Walitt BT (2011) The development of fibromyalgia—I: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 152:291–299CrossRefPubMed
39.
Joharatnam N, McWilliams DF, Wilson D, Wheeler M, Pande I, Walsh DA (2015) A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis. Arthritis Res Ther 17:11CrossRefPubMedPubMedCentral
40.
Boyden SD, Hossain IN, Wohlfahrt A, Lee YC (2016) Non-inflammatory causes of pain in patients with rheumatoid arthritis. Curr Rheumatol Rep 18:30CrossRefPubMed
41.
Masala IF, Caso F, Sarzi-Puttini P, Salaffi F, Atzeni F (2017) Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. Clin Exp Rheumatol 35:S127–S131
42.
Dhondt W, Willaeys T, Verbruggen LA, Oostendorp RA, Duquet W (1999) Pain threshold in patients with rheumatoid arthritis and effect of manual oscillations. Scand J Rheumatol 28:88–93CrossRefPubMed
43.
Leffler AS, Kosek E, Lerndal T, Nordmark B, Hansson P (2002) Somatosensory perception and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from rheumatoid arthritis. Eur J Pain 6:161–176CrossRefPubMed
44.
Meeus M, Vervisch S, De Clerck LS, Moorkens G, Hans G, Nijs F (2012) Central sensitization in patients with rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 41:556–567CrossRefPubMed
45.
Bliddal H, Danneskiold-Samsøe B (2007) Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol 21:391–402CrossRefPubMed
46.
Kristensen LE, Bliddal H, Christensen R, Karlsson JA, Gülfe A, Saxne T et al (2014) Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort. Arthritis Care Res (Hoboken) 66:173–179CrossRef
47.
Di Carlo M, Becciolini A, Lato V, Crotti C, Favalli EG, Salaffi F (2017) The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol 44:279–285CrossRefPubMed